- Faculty
- BR1DGE
Michael Haller
University of Florida, Florida, USA
Screening for T1D allows us to identify those with the disease well in advance of glycemic abnormalities and is a prerequisite to the advancement of therapies capable of delaying and one day preventing T1D
Dr. Haller is Professor and Chief of Pediatric Endocrinology at the University of Florida where he coordinates an active research team focused on the prediction, prevention, and reversal of type 1 diabetes. Dr. Haller is an active investigator in the NIH funded Type 1 Diabetes TrialNet and serves as the PI of the University of Florida TrialNet Clinical Center. Dr. Haller has lead groundbreaking pilot study demonstrating the efficacy of Thymogloublin in patients with new onset and established type 1 diabetes. Dr. Haller has published over 200 peer reviewed manuscripts and book chapters and in the last 5 years has received over $10 million dollars in research funding. Dr. Haller currently sits in the Silverstein Family Eminent Scholar Chair in support of his work in pediatric type 1 diabetes.